Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities
−Removed: Our common stock is listed on Nasdaq under the trading symbol “ARCT”.
Holders of Common Stock
−Removed: As of March 1, 2020, there were 23 holders of record of our common stock.
+Added: As of February 24, 2021, there were 18 holders of record of our common stock.
As of such date, there were 26,280,275 shares of our common stock outstanding.
3 unchanged sentences
Recent Sales of Unregistered Securities
−Removed: In connection with the Third Amendment executed on June 18, 2019, Ultragenyx purchased 2.4 million shares of our common stock for $24.0 million in a private offering exempt from the registration requirements of the Securities Act pursuant to Regulation D.
Issuer and Affiliated Purchaser - Purchases of Equity Securities
−Removed: We completed the sale of our intangible assets related to the ADAIR technology during fiscal year 2018.
−Removed: Pursuant to the asset purchase agreement for ADAIR, we received a 30% ownership interest in the common stock of a privately held company in consideration for the sale of the ADAIR technology.
−Removed: As of December 31, 2019, we hold a 19% ownership interest due to the issuance of common stock by the privately held company.
+Added: During the fiscal year 2018, we completed the sale of our intangible assets related to the ADAIR technology.
+Added: Pursuant to the asset purchase agreement for ADAIR, we received a 30% ownership interest in the common stock of Vallon Pharmaceuticals, Inc.
+Added: (“Vallon”) in consideration for the sale of the ADAIR technology.
+Added: As of December 31, 2020, we held a 19% ownership interest due to the dilutive issuances of common stock by Vallon.
+Added: Vallon completed an initial public offering and began trading on The Nasdaq Capital Market under the ticker “VLON” in February 2021.
+Added: After this offering and other previous stock issuances of Vallon, Arcturus owns 843,750 shares of Vallon’s total post-IPO 6,811,122 outstanding shares, or approximately 12%.
+Added: Five Year Performance Graph
+Added: The annual changes for the five-year period shown in the graph below are based on the assumption that $100 had been invested in Company common stock, the Nasdaq Composite Index, and the Nasdaq Biotechnology Index on December 31, 2015.
+Added: With respect to “Market Information,” our common stock is listed on Nasdaq under the trading symbol “ARCT”.
Selected Financial Data
−Removed: The following tables set forth a summary of our historical financial data as of, and for the periods ended on, the dates indicated.
−Removed: We have derived the statement of operations data and balance sheet data from our audited financial statements (in thousands).
−Removed: You should read the selected financial data in conjunction with the related notes and “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” both of which are included elsewhere in this report.
−Removed: For the Year Ended December 31,
−Removed: Collaboration revenue
−Removed: Research and development, net
−Removed: General and administrative
−Removed: Net loss from operations
−Removed: Net loss per share, basic and diluted
−Removed: Weighted-average shares outstanding, basic and
−Removed: Working capital
−Removed: Shareholders' equity (deficit)
+Added: The Company has elected to comply with Item 301 of Regulation S-K as amended effective February 10, 2021, and is omitting this disclosure in reliance thereon.
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.